Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/17858
Título
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Autor(es)
Pascual, Tomás | Martin, Miguel | Fernández-Martínez, Aranzazu | Paré, Laia | Alba, Emilio | Rodríguez-Lescure, Álvaro | Perrone, Giuseppe | Cortés, Javier | Morales, Serafín | Lluch, Ana | Urruticoechea, Ander | González-Farré, Blanca | Galván, Patricia | Jares, Pedro | Rodriguez, Adela | Chic, Nuria | Righi, Daniela | Cejalvo, Juan Miguel | Tonini, Giuseppe | Adamo, Barbara | Vidal, Maria | Villagrasa, Patricia | Muñoz, Montserrat | Prat, Aleix
Fecha de publicación
2019-04-26
Idioma
Inglés
Tipo de documento
research article
Resumen
Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estrogen receptor (ER), progesterone receptor (PR) and Ki67 tumor cells, was derived in a combined cohort of 5 studies (training dataset) and tested in a combined cohort of 3 studies. The performance of NOLUS was estimated using Area Under the ROC Curve (AUC). Results: In the training dataset (n = 903) and compared to luminal disease, non-luminal disease had lower percentage of ER-positive cells (median 65.2 vs. 86.2%, p
Palabras clave
DOI
Aparece en las colecciones
Acceso a texto completo